Key Highlights
- ENDRA Life Sciences (NASDAQ:NDRA) recorded a third-quarter net loss of USD 1,528,528, slightly below the USD 1,595,959 loss a year earlier, with no Revenue in either period.
- Third-quarter general and administrative expenses rose 72% to USD 1,538,883, as professional fees climbed to USD 814,812 from USD 312,139.
- Cash stood at USD 4,941,526 on September 30, 2026, of which about USD 3.4 million is restricted under an agreement with an ASP Isotopes affiliate.
- Nine-month net loss narrowed to USD 2,680,017 from USD 3,858,201, helped by USD 3,069,929 of gains on the Fair Value of digital assets.
Merger With ASP Isotopes Shapes a Quiet Quarter
ENDRA Life Sciences (NASDAQ:NDRA) develops TAEUS, a technology designed to assess liver tissue using ultrasound, and has yet to generate revenue. In its Quarterly Report filed November 16, 2026, the company said it had no revenue and no Cost of Goods Sold in the quarter ended September 30, 2026 or the year-earlier quarter. It signed a Merger agreement on June 25, 2026 with ASP Isotopes and related entities, under which a merger Subsidiary will combine with Noble Africa, a unit of ASP Isotopes, leaving Noble Africa as a Wholly Owned Subsidiary of ENDRA.
Under the terms, ASP Isotopes will contribute its stake in Renergen to Noble Africa for 55,500,000 Class B units before the merger takes effect. Existing ENDRA common shares would be reclassified as Class A common stock, and the Class B shares issued to ASP Isotopes would carry 10 votes each.
Professional Fees Lift Overhead While Research Spending Shrinks
Research and development expenses were USD 176,280 for the quarter, down 59% from USD 432,113, as development of the initial TAEUS product wound down. Sales and Marketing expense fell to zero from USD 45,285 after a first-quarter 2026 restructuring. General and administrative expenses rose by USD 645,578, or 72%, to USD 1,538,883. Wage costs were USD 439,997, including USD 357,007 of stock compensation, and professional fees covering legal, audit and Investor relations reached USD 814,812.
Other income was USD 186,634, compared with a USD 225,256 loss a year earlier, driven by a USD 509,920 gain on digital Assets and USD 246,867 of digital asset management and performance fees, partly offset by a USD 77,169 Warrant Liability loss. For nine months, general and administrative expenses rose 60% to USD 4,175,721, while other income reached USD 2,692,150.
Cash Is Tied Up and Going Concern Doubt Hinges on Closing
The company held USD 4,941,526 of cash, about USD 3.4 million of it restricted under a deposit account control agreement. It sold securities to an ASP Isotopes affiliate in May 2026 for gross proceeds of USD 3.8 million, but a side letter may require it to return some or all of that money and to keep USD 3.8 million segregated until closing or repayment.
Operating activities used USD 3,799,792 in nine months, against USD 3,570,847 a year earlier, while financing provided USD 4,157,686 from common stock sales. Management believes cash should last through the expected closing, but says that without the merger there is substantial doubt about continuing as a going concern. A Nasdaq panel hearing on stockholders' Equity below the USD 2.5 million minimum was also pending when the merger agreement was negotiated. Shares outstanding were 1,499,838 on November 16, 2026.
Where Things Stand
ENDRA Life Sciences (NASDAQ:NDRA) is a pre-revenue company whose near-term path runs through the ASP Isotopes merger. The USD 1.5 million quarterly loss was little changed from a year earlier, cash of USD 4.9 million is partly restricted, and the filing flags going concern doubt if the deal does not close. Watch for stockholder approval and the registration statement, the outcome of the Nasdaq equity compliance process, any repayment Demand tied to the May private placement, and whether the TAEUS liver De Novo submission stays delayed.






Please wait processing your request...